Veracyte (VCYT) Competitors $27.51 -0.07 (-0.25%) Closing price 07/3/2025 03:36 PM EasternExtended Trading$27.67 +0.16 (+0.58%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, OPCH, RDNT, BTSG, SHC, and SGRYShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), and Surgery Partners (SGRY). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Veracyte (NASDAQ:VCYT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations. Is VCYT or ADPT more profitable? Veracyte has a net margin of 7.13% compared to Adaptive Biotechnologies' net margin of -74.84%. Veracyte's return on equity of 6.14% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Veracyte7.13% 6.14% 5.60% Adaptive Biotechnologies -74.84%-62.79%-24.55% Does the media refer more to VCYT or ADPT? In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Veracyte. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 3 mentions for Veracyte. Veracyte's average media sentiment score of 0.56 beat Adaptive Biotechnologies' score of 0.41 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, VCYT or ADPT? Veracyte has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Do analysts rate VCYT or ADPT? Veracyte presently has a consensus price target of $40.90, suggesting a potential upside of 48.67%. Adaptive Biotechnologies has a consensus price target of $10.57, suggesting a potential downside of 11.73%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do insiders & institutionals hold more shares of VCYT or ADPT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, VCYT or ADPT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$463.39M4.65$24.14M$0.4167.10Adaptive Biotechnologies$189.53M9.60-$159.49M-$0.96-12.48 SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15B$6.95B$5.55B$9.04BDividend YieldN/A1.21%5.22%4.00%P/E Ratio67.1026.6327.6420.24Price / Sales4.6598.68418.75118.07Price / Cash26.5321.0936.8958.10Price / Book1.814.748.035.67Net Income$24.14M$173.18M$3.18B$249.21M7 Day Performance0.47%1.33%2.93%3.28%1 Month Performance0.18%-1.67%1.72%3.95%1 Year Performance27.78%25.08%34.39%20.98% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.6069 of 5 stars$27.51-0.3%$40.90+48.7%+27.8%$2.15B$463.39M67.10790ADPTAdaptive Biotechnologies3.3167 of 5 stars$11.65-1.2%$10.57-9.3%+238.3%$1.77B$189.53M-12.14790News CoverageGap UpBEAMBeam Therapeutics2.5257 of 5 stars$17.01+1.3%$48.75+186.6%-13.3%$1.71B$63.52M-3.69510GHGuardant Health3.8505 of 5 stars$52.04+2.3%$53.76+3.3%+74.8%$6.45B$739.02M-15.352,021Insider TradeTWSTTwist Bioscience4.4662 of 5 stars$36.79+2.4%$50.40+37.0%-21.4%$2.20B$312.97M-11.32990Positive NewsTXG10x Genomics4.6183 of 5 stars$11.58-1.3%$14.96+29.2%-30.5%$1.43B$610.78M-8.911,240OPCHOption Care Health4.3618 of 5 stars$32.48+0.7%$35.50+9.3%+12.4%$5.32B$5.00B26.198,088Positive NewsRDNTRadNet3.6701 of 5 stars$56.91-0.4%$69.60+22.3%-5.8%$4.27B$1.83B-132.3511,021BTSGBrightSpring Health Services1.6327 of 5 stars$23.59+0.2%$24.90+5.6%+98.5%$4.15B$11.27B84.2535,000Analyst UpgradeSHCSotera Health2.9548 of 5 stars$11.12-1.8%$16.00+43.9%0.0%$3.16B$1.10B139.023,000SGRYSurgery Partners2.4284 of 5 stars$22.23+1.3%$33.56+50.9%-5.4%$2.85B$3.17B-14.5315,000 Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors Option Care Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
